March 7, 2002
John J. Engel
Executive Vice President, PerkinElmer;
President, PerkinElmer Life Sciences
$1 Billion Invested in 18 Months
What is the history of your organization’s involvement in life sciences?
Engel: Greg Summe, our chairman and CEO, recognized soon after coming to the company in 1998 that life sciences was an attractive high-growth market, and one in which we should invest. We have significantly strengthened our life sciences business and have aggressively acquired additional assets. Over the past 18 months, we have invested more than $1 billion in our life sciences business, building on our strong detection and genetic disease screening foundation. About a year ago, we acquired NEN Life Sciences, a leader in reagents and labeling chemistries. In November 2001, we completed the acquisition of Packard BioScience, adding world-class automated liquid handling and sample preparation capability and an exciting array of biochip technologies to our portfolio.
Today we are a global leader and enjoy strong competitive positions in a number of attractive life sciences markets—we are No. 1 in drug screening, No. 1 in automated liquid handling and sample preparation, and No. 1 in genetic disease screening.
What is your vision for the development of the life sciences market?
Engel: PerkinElmer Life Sciences’ focus in drug discovery is to increase the productivity of our customers’ drug discovery processes, thus enabling them to successfully get more drugs—and more effective drugs—to the market faster. So what inspires me to come to work every day is knowing that the products and solutions we are working on play a key role in improving the quality and longevity of people’s lives. That’s a very powerful motivator, and there are not many people who can say that about their company or their jobs.
What organizational assets have you developed to serve this community?
Engel: Our key organizational assets include: leading-edge technology, a portfolio of products and capabilities that is both broad and deep, an extensive application-focused global sales and service front-end, a high-performance culture that includes operational excellence and six sigma as its underpinnings, and a PerkinElmer brand that is recognized around the world.
What products and services does your company provide to the life sciences market?
Engel: We think of our life sciences business in two parts: drug discovery tools and genetic disease screening. Drug discovery tools represent about 80 percent of our business, and genetic disease screening accounts for 20 percent. These two business enterprises are built on a strong foundation of four pillars that support every customer application: liquid handling and sample preparation, chemistry, detection, and informatics.
Our drug discovery business offers products that serve three market segments. Each market segment is large and growing fast: high-throughput genetic disease screening, functional genomics, and proteomics:
• In genetic disease screening, our goal is to help our customers provide complete, cost-effective quality screening.
• In functional genomics, we focus on three applications: automated nucleic acid sample preparation, microarrays, and SNP scoring.
• In proteomics, we provide gel-based proteomics, protein arrays, and a live cell imaging platform.
Return to main index page.